Patents by Inventor Yasuhito Hamaguchi

Yasuhito Hamaguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD-20-SPECIFIC ANTIBODIES AND METHODS OF EMPLOYING SAME
    Publication number: 20170088625
    Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
    Type: Application
    Filed: July 13, 2016
    Publication date: March 30, 2017
    Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
  • CD-20 specific antibodies and methods of employing same
    Patent number: 9416187
    Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 16, 2016
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Jonathan C. Poe
  • Anti-CD19 antibodies and uses in B cell disorders
    Patent number: 9260530
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: February 16, 2016
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS
    Publication number: 20140056896
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 27, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • Anti-CD19 antibodies and uses in B cell disorders
    Patent number: 8444973
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 21, 2013
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS
    Publication number: 20130084294
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: September 4, 2012
    Publication date: April 4, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • ANTI-CD19 ANTIBODIES AND USES IN B CELL DISORDERS
    Publication number: 20110104150
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: September 17, 2010
    Publication date: May 5, 2011
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • ANTI-CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASE
    Publication number: 20100158901
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 24, 2010
    Applicant: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY
    Publication number: 20090285808
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: March 10, 2009
    Publication date: November 19, 2009
    Applicant: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • Cd-20 specific antibodies and methods of employing same
    Publication number: 20090136516
    Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
    Type: Application
    Filed: May 7, 2004
    Publication date: May 28, 2009
    Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
  • Anti-CD19 antibody therapy for autoimmune disease
    Publication number: 20060263357
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: May 5, 2006
    Publication date: November 23, 2006
    Inventors: Thomas Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • Anti-CD19 antibodies and uses in oncology
    Publication number: 20060233791
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: February 15, 2006
    Publication date: October 19, 2006
    Inventors: Thomas Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa